Circulating exosomes may provide a more sensitive platform to monitor disease progression compared to circulating tumor cells.

Pawlowski, Traci; Spetzler, David; Tinder, Teresa L.; Kimbrough, J. C.; Deng, Tao; Kim, J.; Ellis, P.; Tyrell, Annemarie; Kennedy, Patrick; Kuslich, Christine

doi:10.1200/jco.2010.28.15_suppl.10580

Cited by 2 publications

(2 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Exo are drawing attention in the field of liquid biopsy, as they bear an enormous potential to enable personalized medicine (He and Zeng, 2016;Zhou et al, 2020;Li et al, 2021). Already in 2010, the American Society of Clinical Oncology suggested that blood Exo would be a better choice than CTCs for monitoring cancer progression (Pawlowski et al, 2010). In fact, a higher level of blood Exo is found in tumor patients, respect to healthy individuals, independently of tumor histology (Zhong et al, 2021).…”

Section: Exosomes For Liquid Biopsymentioning

confidence: 99%

Exosomes: Key tools for cancer liquid biopsy

Panfoli¹,

Bruschi²,

Candiano³

2022

Biocell

View full text Add to dashboard Cite

Precision medicine is based on the identification of biomarkers of tumor development and progression. Liquid biopsy is at the forefront of the ability to gather diagnostic and prognostic information on tumors, as it can be noninvasively performed prior or during treatment. Liquid biopsy mostly utilizes circulating tumor cells, or free DNA, but also exosomes. The latter are nanovesicles secreted by most cell types, found in any body fluid that deliver proteins, nucleic acids and lipids to nearby and distant cells with a unique homing ability. Exosomes function in signalling between the tumor microenvironment and the rest of the body, promoting metastasis, immune remodelling and drug resistance. Exosomes are emerging as a key tool in precision medicine for cancer liquid biopsy, as they efficiently preserve their biomarker cargo. Moreover, exosomes strongly resemble the parental cell, which can help in assessing the oxidative and metabolic state of the donor cell. In this respect, exosomes represent one of the most promising new tools to fight cancer. This review will discuss the clinical applications of profiling exosomal proteins and lipids by high-throughput proteomics and metabolomics, and nucleic acids by next generation sequencing, as well as how this may allow cancer diagnosis, therapy response monitoring and recurrence detection.

show abstract

Section: Exosomes For Liquid Biopsymentioning

confidence: 99%

Exosomes: Key tools for cancer liquid biopsy

Panfoli¹,

Bruschi²,

Candiano³

2022

Biocell

View full text Add to dashboard Cite

show abstract

“…It is possible to design a molecular marker common between the exosomes and CTCs for better understanding of the metastasis process. American Society of Clinical Oncology suggests circulating exosomes may provide an alternative platform for monitoring disease progression as opposed to CTCs 21. Several ongoing studies have aimed at quantifying a stress protein or other biomarkers in the blood and urine for monitoring and early diagnosis of malignant solid tumors (https://clinicaltrials.gov).…”

Section: Introductionmentioning

confidence: 99%

<p>Common molecular markers between circulating tumor cells and blood exosomes in colorectal cancer: a systematic and analytical review</p>

Vafaei¹,

Fattahi²,

Ebrahimi³

et al. 2019

CMAR

View full text Add to dashboard Cite

Nearly half of patients with colorectal cancer (CRC), the third leading cause of cancer deaths worldwide, are diagnosed in the late stages of the disease. Appropriate treatment is not applied in a timely manner and nearly 90% of the patients who experience metastasis ultimately die. Timely detection of CRC can increase the five-year survival rate of patients. Existing histopathological and molecular classifications are insufficient for prediction of metastasis, which limits approaches to treatment. Detection of reliable cancer-related biomarkers can improve early diagnosis, prognosis, and treatment response prediction and recurrence risk. Circulating tumor cells (CTCs) and exosomes in peripheral blood can be used in a liquid biopsy to assess the status of a tumor. Exosomes are abundant and available in all fluids of the body, have a high half-life and are released by most cells. Tumor-derived exosomes are released from primary tumors or CTCs with selective cargo that represents the overall tumor. The current systematic review highlights new trends and approaches in the detection of CRC biomarkers to determine tumor signatures using CTC and exosomes. When these are combined, they could be used to guide molecular pathology and can revolutionize detection tools. Relevant observational studies published until July 24, 2019 which evaluated the expression of tumor markers in CTCs and exosomes were searched in PubMed, Scopus, Embase, and ISI Web of Science databases. The extracted biomarkers were analyzed using String and EnrichR tools.

show abstract

Circulating exosomes may provide a more sensitive platform to monitor disease progression compared to circulating tumor cells.

Cited by 2 publications

References 0 publications

Exosomes: Key tools for cancer liquid biopsy

Exosomes: Key tools for cancer liquid biopsy

<p>Common molecular markers between circulating tumor cells and blood exosomes in colorectal cancer: a systematic and analytical review</p>

Contact Info

Product

Resources

About